RU2017145650A - Ингибиторы тирозинкиназы брутона - Google Patents
Ингибиторы тирозинкиназы брутона Download PDFInfo
- Publication number
- RU2017145650A RU2017145650A RU2017145650A RU2017145650A RU2017145650A RU 2017145650 A RU2017145650 A RU 2017145650A RU 2017145650 A RU2017145650 A RU 2017145650A RU 2017145650 A RU2017145650 A RU 2017145650A RU 2017145650 A RU2017145650 A RU 2017145650A
- Authority
- RU
- Russia
- Prior art keywords
- unsubstituted
- substituted
- carboxamide
- piperidin
- compound according
- Prior art date
Links
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 57
- -1 3- (4-tert-butylbenzamido) piperidin-1-yl Chemical group 0.000 claims 36
- 125000001072 heteroaryl group Chemical group 0.000 claims 21
- 125000003118 aryl group Chemical group 0.000 claims 19
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 15
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 3
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims 3
- OTPKESFCTVIJSI-CQSZACIVSA-N 3-[[(3R)-1-but-2-ynoylpiperidin-3-yl]amino]-5-(4-methylsulfonylanilino)-1,2,4-triazine-6-carboxamide Chemical compound C(C#CC)(=O)N1C[C@@H](CCC1)NC=1N=NC(=C(N1)NC1=CC=C(C=C1)S(=O)(=O)C)C(=O)N OTPKESFCTVIJSI-CQSZACIVSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- YADCPAXRUJZGER-GFCCVEGCSA-N (3R)-3-[[5-carbamoyl-6-[(3-methyl-1,2-thiazol-5-yl)amino]pyrazin-2-yl]amino]-N,N-dimethylazepane-1-carboxamide Chemical compound C(N)(=O)C=1N=CC(=NC1NC1=CC(=NS1)C)N[C@H]1CN(CCCC1)C(=O)N(C)C YADCPAXRUJZGER-GFCCVEGCSA-N 0.000 claims 1
- AXDRKVAYKSVRHT-OAQYLSRUSA-N 3-[(3R)-3-[(4-tert-butylbenzoyl)amino]piperidin-1-yl]-5-(3-methylanilino)-1,2,4-triazine-6-carboxamide Chemical compound C(C)(C)(C)C1=CC=C(C(=O)N[C@H]2CN(CCC2)C=2N=NC(=C(N2)NC=2C=C(C=CC2)C)C(=O)N)C=C1 AXDRKVAYKSVRHT-OAQYLSRUSA-N 0.000 claims 1
- RZWDONNOUHBZTO-HSZRJFAPSA-N 3-[(3R)-3-[(4-tert-butylbenzoyl)amino]piperidin-1-yl]-5-(3-pyrimidin-2-ylanilino)-1,2,4-triazine-6-carboxamide Chemical compound C(C)(C)(C)C1=CC=C(C(=O)N[C@H]2CN(CCC2)C=2N=NC(=C(N2)NC2=CC(=CC=C2)C2=NC=CC=N2)C(=O)N)C=C1 RZWDONNOUHBZTO-HSZRJFAPSA-N 0.000 claims 1
- RJVISCHEJZVWGM-OAQYLSRUSA-N 3-[(3R)-3-[(4-tert-butylbenzoyl)amino]piperidin-1-yl]-5-(4-methylanilino)-1,2,4-triazine-6-carboxamide Chemical compound C(C)(C)(C)C1=CC=C(C(=O)N[C@H]2CN(CCC2)C=2N=NC(=C(N2)NC2=CC=C(C=C2)C)C(=O)N)C=C1 RJVISCHEJZVWGM-OAQYLSRUSA-N 0.000 claims 1
- MDQRIUQNZANBTI-HXUWFJFHSA-N 3-[(3R)-3-[(4-tert-butylbenzoyl)amino]piperidin-1-yl]-5-(4-methylsulfonylanilino)-1,2,4-triazine-6-carboxamide Chemical compound C(C)(C)(C)C1=CC=C(C(=O)N[C@H]2CN(CCC2)C=2N=NC(=C(N2)NC2=CC=C(C=C2)S(=O)(=O)C)C(=O)N)C=C1 MDQRIUQNZANBTI-HXUWFJFHSA-N 0.000 claims 1
- JOAUAXDSUNVTQQ-GOSISDBHSA-N 3-[(3R)-3-[(4-tert-butylbenzoyl)amino]piperidin-1-yl]-5-[(5-fluoropyridin-3-yl)amino]-1,2,4-triazine-6-carboxamide Chemical compound C(C)(C)(C)C1=CC=C(C(=O)N[C@H]2CN(CCC2)C=2N=NC(=C(N2)NC=2C=NC=C(C2)F)C(=O)N)C=C1 JOAUAXDSUNVTQQ-GOSISDBHSA-N 0.000 claims 1
- UCBIZXOMSGKHIB-JOCHJYFZSA-N 3-[(3R)-3-[(4-tert-butylbenzoyl)amino]piperidin-1-yl]-5-[4-(1,3-oxazol-2-yl)anilino]-1,2,4-triazine-6-carboxamide Chemical compound C(C)(C)(C)C1=CC=C(C(=O)N[C@H]2CN(CCC2)C=2N=NC(=C(N2)NC2=CC=C(C=C2)C=2OC=CN2)C(=O)N)C=C1 UCBIZXOMSGKHIB-JOCHJYFZSA-N 0.000 claims 1
- OJKTZJQBFBYXAK-HSZRJFAPSA-N 3-[(3r)-3-[(4-tert-butylbenzoyl)amino]piperidin-1-yl]-5-(4-pyrimidin-2-ylanilino)-1,2,4-triazine-6-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)N[C@H]1CN(C=2N=C(NC=3C=CC(=CC=3)C=3N=CC=CN=3)C(C(N)=O)=NN=2)CCC1 OJKTZJQBFBYXAK-HSZRJFAPSA-N 0.000 claims 1
- QOXFMUBWQHGRRX-BIENSFFJSA-N 3-[[(3R)-1-[(E)-4-(dimethylamino)but-2-enoyl]piperidin-3-yl]amino]-5-(4-methylsulfonylanilino)-1,2,4-triazine-6-carboxamide Chemical compound CN(C/C=C/C(=O)N1C[C@@H](CCC1)NC=1N=NC(=C(N1)NC1=CC=C(C=C1)S(=O)(=O)C)C(=O)N)C QOXFMUBWQHGRRX-BIENSFFJSA-N 0.000 claims 1
- GCDSJMZGWCQCRU-UHFFFAOYSA-N 5-fluoropyridine-3-carboxamide Chemical compound NC(=O)C1=CN=CC(F)=C1 GCDSJMZGWCQCRU-UHFFFAOYSA-N 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- NFUGIXXXQFTUTB-RQNOJGIXSA-N C(C)(=O)N[C@@H]1CC[C@H](CC1)NC=1N=C(C(=NC=1CC)C(=O)N)NC1=CC(=C(C=C1)N1CCC(CC1)N1CCN(CC1)C)C Chemical compound C(C)(=O)N[C@@H]1CC[C@H](CC1)NC=1N=C(C(=NC=1CC)C(=O)N)NC1=CC(=C(C=C1)N1CCC(CC1)N1CCN(CC1)C)C NFUGIXXXQFTUTB-RQNOJGIXSA-N 0.000 claims 1
- MASOCRMWDFZZAF-OAQYLSRUSA-N C(N)(=O)C=1N=CC(=NC1NC1=CC=C(C=C1)C1CCOCC1)N1C[C@@H](CCC1)NC(=O)C=1C=CC=2N(C1O)C=CN2 Chemical compound C(N)(=O)C=1N=CC(=NC1NC1=CC=C(C=C1)C1CCOCC1)N1C[C@@H](CCC1)NC(=O)C=1C=CC=2N(C1O)C=CN2 MASOCRMWDFZZAF-OAQYLSRUSA-N 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- LUIXLONJINHXKS-HSZRJFAPSA-N N-[(3R)-1-[5-carbamoyl-6-[4-(oxan-4-yl)anilino]pyrazin-2-yl]piperidin-3-yl]imidazo[1,2-a]pyridine-6-carboxamide Chemical compound C(N)(=O)C=1N=CC(=NC1NC1=CC=C(C=C1)C1CCOCC1)N1C[C@@H](CCC1)NC(=O)C=1C=CC=2N(C1)C=CN2 LUIXLONJINHXKS-HSZRJFAPSA-N 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000006312 cyclopentyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562169935P | 2015-06-02 | 2015-06-02 | |
| US201562169941P | 2015-06-02 | 2015-06-02 | |
| US201562169945P | 2015-06-02 | 2015-06-02 | |
| US62/169,935 | 2015-06-02 | ||
| US62/169,945 | 2015-06-02 | ||
| US62/169,941 | 2015-06-02 | ||
| US201562249338P | 2015-11-01 | 2015-11-01 | |
| US201562249336P | 2015-11-01 | 2015-11-01 | |
| US201562249340P | 2015-11-01 | 2015-11-01 | |
| US62/249,338 | 2015-11-01 | ||
| US62/249,336 | 2015-11-01 | ||
| US62/249,340 | 2015-11-01 | ||
| PCT/US2016/035489 WO2016196776A2 (en) | 2015-06-02 | 2016-06-02 | Inhibitors of bruton's tyrosine kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017145650A true RU2017145650A (ru) | 2019-07-15 |
| RU2017145650A3 RU2017145650A3 (enExample) | 2019-11-22 |
Family
ID=57441893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017145650A RU2017145650A (ru) | 2015-06-02 | 2016-06-02 | Ингибиторы тирозинкиназы брутона |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180305348A1 (enExample) |
| EP (1) | EP3310776A4 (enExample) |
| JP (1) | JP2018522823A (enExample) |
| KR (1) | KR20180021740A (enExample) |
| CN (1) | CN107709315A (enExample) |
| AU (2) | AU2016270907B2 (enExample) |
| BR (1) | BR112017025986A2 (enExample) |
| CA (1) | CA2987054A1 (enExample) |
| IL (1) | IL255831A (enExample) |
| MA (1) | MA42623A (enExample) |
| MX (1) | MX2017015574A (enExample) |
| RU (1) | RU2017145650A (enExample) |
| SG (1) | SG10201911523YA (enExample) |
| WO (1) | WO2016196776A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY203083A (en) * | 2016-12-21 | 2024-06-07 | Acerta Pharma Bv | Imidazopyrazine inhibitors of bruton's tyrosine kinase |
| KR101956815B1 (ko) * | 2017-02-14 | 2019-03-12 | 한국화학연구원 | 트리아졸로피리다진 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| CN109384774B (zh) * | 2017-08-11 | 2023-02-17 | 中国科学院上海药物研究所 | 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用 |
| CN108530450B (zh) * | 2018-05-03 | 2021-03-30 | 赖建智 | 具有egfr抑制活性的化合物、制备方法及其在疾病治疗中的应用 |
| KR102797697B1 (ko) | 2018-05-25 | 2025-04-22 | 에이2에이 파마수티칼스, 잉크. | 신종 항암제 후보로서, 매우 강력한 tacc3 억제제 |
| CN113412259B (zh) | 2018-10-15 | 2024-07-16 | 紐力克斯治疗公司 | 通过泛素蛋白酶体途径降解btk的双官能化合物 |
| HRP20250048T1 (hr) | 2018-10-22 | 2025-03-28 | Alumis Inc. | Inhibitori tyk2 i njihova uporaba |
| WO2020167518A1 (en) * | 2019-02-13 | 2020-08-20 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| AU2020272937B2 (en) | 2019-04-09 | 2024-09-26 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for Cbl-b inhibition, and use of a Cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| JP7587528B2 (ja) | 2019-05-17 | 2024-11-20 | ニューリックス セラピューティクス，インコーポレイテッド | Ｃｂｌ－ｂ阻害のためのシアノシクロブチル化合物及びその使用 |
| CA3144450A1 (en) | 2019-06-26 | 2020-12-30 | Nurix Therapeutics, Inc. | Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof |
| US12121540B2 (en) | 2019-09-24 | 2024-10-22 | Nurix Therapeutics, Inc. | CBL inhibitors and compositions for use in adoptive cell therapy |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| MX2022006672A (es) | 2019-12-04 | 2022-08-08 | Nurix Therapeutics Inc | Compuestos bifuncionales para la degradacion de btk a traves de la via de proteosomas de ubiquitina. |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| BR112022022220A2 (pt) * | 2020-06-01 | 2022-12-13 | Wigen Biomedicine Tech Shanghai Co Ltd | Composto, composição farmacêutica, uso do composto, e método para tratar, regular e/ou prevenir uma doença relacionada a uma proteína mutante de egfr |
| WO2022071772A1 (ko) * | 2020-09-29 | 2022-04-07 | (주)메디톡스 | 단백질 키나제 저해제 및 그의 용도 |
| MX2023011883A (es) | 2021-04-08 | 2023-11-09 | Nurix Therapeutics Inc | Terapias combinadas con compuestos inhibidores de cbl-b. |
| WO2022221194A1 (en) * | 2021-04-12 | 2022-10-20 | A2A Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
| CA3223769A1 (en) * | 2021-07-01 | 2023-01-05 | Xinglu ZHOU | Bruton's tyrosine kinase and mutant degrader, composition and application thereof |
| WO2023076303A1 (en) | 2021-10-26 | 2023-05-04 | Nurix Therapeutics, Inc. | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
| WO2023088477A1 (zh) * | 2021-11-22 | 2023-05-25 | 杭州和正医药有限公司 | 一种可降解btk激酶的多功能化合物、组合物及应用 |
| EP4499625A4 (en) | 2022-03-24 | 2026-03-18 | A2A Pharmaceuticals Inc | CANCER COMPOSITIONS AND TREATMENT METHODS |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4622047B2 (ja) * | 1999-06-09 | 2011-02-02 | アステラス製薬株式会社 | 新規なヘテロ環カルボキサミド誘導体 |
| AU5107900A (en) * | 1999-06-09 | 2000-12-28 | Yamanouchi Pharmaceutical Co., Ltd. | Novel heterocyclic carboxamide derivatives |
| JP2014005206A (ja) * | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
| JP5878178B2 (ja) * | 2011-09-30 | 2016-03-08 | 大鵬薬品工業株式会社 | １，２，４−トリアジン−６−カルボキサミド誘導体 |
| EP2763976B1 (en) * | 2011-10-05 | 2016-05-18 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| SG11201402570QA (en) * | 2011-11-23 | 2014-06-27 | Portola Pharm Inc | Pyrazine kinase inhibitors |
| KR20140108594A (ko) * | 2012-01-10 | 2014-09-11 | 에프. 호프만-라 로슈 아게 | 피리다진 아미드 화합물 및 syk 저해제로서의 이의 용도 |
| WO2013108754A1 (ja) * | 2012-01-17 | 2013-07-25 | アステラス製薬株式会社 | ピラジンカルボキサミド化合物 |
| US20140113931A1 (en) * | 2012-06-22 | 2014-04-24 | Portola Pharmaceuticals, Inc. | Substituted picolinamide kinase inhibitors |
| US9040530B2 (en) * | 2012-06-22 | 2015-05-26 | Portola Pharmaceuticals, Inc. | 1,2,4-triazine-6-carboxamide kinase inhibitors |
| WO2014135473A1 (en) * | 2013-03-05 | 2014-09-12 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| WO2014153280A1 (en) * | 2013-03-22 | 2014-09-25 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| CN104262328B (zh) * | 2013-09-18 | 2016-09-07 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
| EP3077388A1 (en) * | 2013-12-05 | 2016-10-12 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase |
-
2016
- 2016-06-02 MA MA042623A patent/MA42623A/fr unknown
- 2016-06-02 RU RU2017145650A patent/RU2017145650A/ru not_active Application Discontinuation
- 2016-06-02 AU AU2016270907A patent/AU2016270907B2/en not_active Ceased
- 2016-06-02 BR BR112017025986A patent/BR112017025986A2/pt not_active IP Right Cessation
- 2016-06-02 CA CA2987054A patent/CA2987054A1/en not_active Abandoned
- 2016-06-02 SG SG10201911523YA patent/SG10201911523YA/en unknown
- 2016-06-02 JP JP2017560655A patent/JP2018522823A/ja active Pending
- 2016-06-02 EP EP16804424.6A patent/EP3310776A4/en not_active Withdrawn
- 2016-06-02 CN CN201680035113.2A patent/CN107709315A/zh active Pending
- 2016-06-02 KR KR1020177037849A patent/KR20180021740A/ko not_active Withdrawn
- 2016-06-02 US US15/579,142 patent/US20180305348A1/en not_active Abandoned
- 2016-06-02 WO PCT/US2016/035489 patent/WO2016196776A2/en not_active Ceased
- 2016-06-02 MX MX2017015574A patent/MX2017015574A/es unknown
-
2017
- 2017-11-21 IL IL255831A patent/IL255831A/en unknown
-
2019
- 2019-07-17 US US16/514,544 patent/US20210070748A1/en not_active Abandoned
-
2020
- 2020-12-11 AU AU2020286332A patent/AU2020286332A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180021740A (ko) | 2018-03-05 |
| MA42623A (fr) | 2018-06-20 |
| WO2016196776A3 (en) | 2017-01-05 |
| CN107709315A (zh) | 2018-02-16 |
| RU2017145650A3 (enExample) | 2019-11-22 |
| EP3310776A4 (en) | 2019-01-16 |
| SG10201911523YA (en) | 2020-02-27 |
| WO2016196776A2 (en) | 2016-12-08 |
| US20210070748A1 (en) | 2021-03-11 |
| BR112017025986A2 (pt) | 2018-08-14 |
| MX2017015574A (es) | 2018-08-09 |
| JP2018522823A (ja) | 2018-08-16 |
| IL255831A (en) | 2018-01-31 |
| AU2016270907B2 (en) | 2020-09-17 |
| EP3310776A2 (en) | 2018-04-25 |
| AU2016270907A1 (en) | 2017-12-07 |
| CA2987054A1 (en) | 2016-12-08 |
| AU2020286332A1 (en) | 2021-01-21 |
| US20180305348A1 (en) | 2018-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522823A5 (enExample) | ||
| JP6895938B2 (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP2021534124A5 (enExample) | ||
| JP6466348B2 (ja) | スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用 | |
| JP2007519754A5 (enExample) | ||
| RU2008112221A (ru) | Соединения ряда изоиндолимидов, их композиции и способы применения | |
| RU2004135066A (ru) | Ингибиторы деацетилазы гистонов | |
| RU2403247C2 (ru) | Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения | |
| RU2009118254A (ru) | Фенилацетамиды в качестве ингибиторов протеинкиназ | |
| WO2014145029A2 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| RU2002121645A (ru) | Производные 2-аминоникотинамида и их применение в качестве ингибиторов vegf-рецептора тирозинкиназы | |
| RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
| SI2961736T1 (en) | Histone demethylase inhibitors | |
| HRP20191821T1 (hr) | Antiproliferativni spojevi i načini njihove uporabe | |
| CA2396590A1 (en) | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | |
| JP2010538076A5 (enExample) | ||
| RU2007108861A (ru) | Трифтометилзамещенные бензамиды в качестве ингибиторов киназ | |
| CA2522435A1 (en) | Inhibitors of akt activity | |
| CA2601508A1 (en) | Cyclopropanecarboxamide derivatives | |
| RU2003132687A (ru) | Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv | |
| RU2006101541A (ru) | Производные пиперазина и способ их применения | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| CA2803055A1 (en) | Heteroaryl compounds and compositions as protein kinase inhibitors | |
| JP2005047905A (ja) | ２−アシルアミノチアゾール誘導体又はその塩 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210716 |